Thanks bear.

I certainly feel that progress is moving along nicely on the science side. My frustration resulted from me fooling myself into believing ZE was further along the scientific development path than it is and that there may be near term opportunities on the business side including a liquidity option for shares. I had no justifiable reasons to fool myself. The information re progress was right in front of my nose.

So I see ZE as a biotech that may have some promise if zen3694 can demonstrate that it really does make a number of SOC cancer drugs effective once again and thus prolongs the lives of patients to a significant enough length to be attractive to the FDA and at least 1 BP.

So the key now is the scientific analysis of the mCRPC trial. If this trial shows very significant positive findings in terms of safety (in a cancer context) and a significant impact on prolonging life it could have the effect of generating significant interest at the FDA. EUDA and various BPs. This in turn could generate business interest, although, based on my very narrow 10 years of experience with RVX and ZCC, given the early stage of the mCRPC trial I doubt any company will be pulling out their cheque books soon.

Also if RVX can salvage some promising results from the BoM trial, by that I mean findings that could result in apabetalone getting NDA approval from the FDA and/or EUDA for apabetalone for some important indication it should boost the the RVX and ZE brands in terms of scientific credibility in the epigenetic field. Then, we could actually be in business and both ZCC and RVX will need to bring in business people to run the companies.

OK, I fell into the dream trap again. My guess is that we are faced with 3 to 6 years of trials ahead of us and that I should sit back and just enjoy the ride.

But anything could happen. RVX and ZE are still alive and kickin.

GLTA

Toinv